Minireviews
Copyright ©The Author(s) 2017.
World J Cardiol. Feb 26, 2017; 9(2): 147-153
Published online Feb 26, 2017. doi: 10.4330/wjc.v9.i2.147
Table 2 Published clinical studies with pediatric cell-based cardiac regeneration
Ref.Study typeDiagnosisNo. of childrenMean age of children (m)SexType of stem cellCell applicationFUPMain results
Lacis et al[30]Case reportDil. CMP13.5 moFBM-MNCIM4 moLV EF from 20% to 41%
Rupp et al[31]Case reportDil. CMP94 mo-16 yrNABM-MNCsIC1-52 mo3 patients HTX, 1 patient died, others improved
Ishigami et al[32] (TICAP study)Controlled studyHLHS7 treated and 7 controls< 6 yrNACDCsIC18 moIncrease in RV EF from 46.9% to 52.1% in treated patients
Rupp et al[33]Case reportHLHS111 moMBMCIC14 moRV EF from 22% to 44%
Rupp et al[34]Case reportDil. CMP12 yearMBMCIC6 moEF from 24% to 45%,
BNP and NYHA decreased
De Lezo et al[35]Case ReportPost-AMI17 moNABM-MNCsIC14 moLV EF from 20% to 43%
Olguntürk et al[36]Case reportDil. CMP26 and 9 yrM, FPBSC after GCSF treatmentIC8 wk, and 6 mo1st patient LV EF from: 16% to 39%; 2nd patient LV EF from 34% to 54%
Limsuwan et al[37]Case reportHF post-AMI19 yrFBMC after GCSF treatmentIC3 moLV EF form 30% to 47%
Zeinaloo et al[38]Case reportDil. CMP111 yrMBM-MSCIC1 yrLV EF from 20% to 42%
Rivas et al[39]Case reportDil. CMP23 and 4 moMPBSC after G-CSF treatmentIC4 moEF from < 30% to > 40%
Bergmane et al[40]Case reportDil. CMP74 mo-17 yrNABMCIM1 yr6 patients controlled, LV EF from 33.5% to 54%
Burkhart et al[41]Case reportHLHS13 mNAUmbilical cord blood derived cellsIM3 moEF increased to 45%